Corporate Banner
Satellite Banner
Technology Networks Header
Friday, October 24, 2014
Technology Networks
 
Register | Sign in
Home Page>News

  News Archive

Merck, Sysmex Collaborate To Develop And Commercialize Blood-Based RAS Biomarker Test
Wednesday, June 04, 2014
Companies to develop and commercialize of a RAS kit for patients with metastatic colorectal cancer (mCRC).

Dako, Merck Collaborate on CDx Test for Tumor Biomarker Analysis
Monday, June 02, 2014
Companies collaborate to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer.

Horizon Completes Acquisition of CombinatoRx from Zalicus
Monday, June 02, 2014
Acquisition of revenue generating and complementary business establishes Horizon’s headquarters in North America.

Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
Monday, June 02, 2014
Companies pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs.

Merck Signs Collaboration Agreement with Sysmex Inostics
Sunday, June 01, 2014
Collaboration for the development and commercialization of a blood-based RAS biomarker test.

G3 Announces Completion of Enrollment in GLOBAL Study with 7,500 Patients
Friday, May 30, 2014
Single largest prospective pan-omic study to identify key biomarkers and central therapeutic targets for cardiovascular diseases has completed enrollment.

QIAGEN, Lilly form CDx Collaboration
Friday, May 30, 2014
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.

FDA Approve QIAGEN PCR Kit For Use With Second Colorectal Cancer Drug
Tuesday, May 27, 2014
Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix® (panitumumab) in treatment of metastatic colorectal cancer.

Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Friday, May 23, 2014
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.

<< 7 8 9 10 11 12 13 >>
Showing Results 91 - 100 of 3486
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv